Abiopharma

🔍 Werdein Jeffrey M. (Executive)

Company: Lake Shore Bancorp, Inc. /MD/ (LSBK)

Report Date: 2026-08-21

Detailed Transactions and Holdings:

• Acquired 23,132 shares of Common Stock at $10.62 per share (Direct)
  Date: 2026-08-21 | Code: M | equity_swap_involved: false | shares_owned_after: 77,387.00 | transaction_form_type: 4 | Footnotes: F1
• Sold 16,525 shares of Common Stock at $17.25 per share (Direct)
  Date: 2026-08-21 | Code: F | equity_swap_involved: false | shares_owned_after: 60,862.00 | transaction_form_type: 4 | Footnotes: F2, F3
• Holds 0 shares of Common Stock (Direct)
  Date: 2026-08-21 | Code: H | nature_of_ownership: By IRA | shares_owned_after: 20,000.00
• Holds 0 shares of Common Stock (Direct)
  Date: 2026-08-21 | Code: H | nature_of_ownership: By ESOP | shares_owned_after: 7,782.00 | Footnotes: F6
• Holds 0 shares of Common Stock (Direct)
  Date: 2026-08-21 | Code: H | nature_of_ownership: By Spouse | shares_owned_after: 2,000.00 | Footnotes: F7
• Sold 23,132 shares of Option (right to buy) at $10.62 per share (Derivative)
  Date: 2026-08-21 | Code: M | Expires: 2026-10-21 | equity_swap_involved: false | transaction_form_type: 4 | Footnotes: F1, F8

Footnotes:

• F1: Exercise price amounted to $10.61342469, which represents the original exercise price of $14.38, updated for the 1.3549 to 1.00 exchange in connection with the Company's mutual to stock conversion, so that the aggregate cost of the options remained unchanged after conversion. This and previous filings present the exercise price rounded up to the nearest whole penny, or $10.62. No fractional shares were issued to the reporting person.
• F2: The number of shares reported as disposed of represents shares withheld by the issuer through net settlement to satisfy the exercise price of the option award and the tax liability incident to the withholding of shares. No shares were sold in the open market.
• F3: Includes 3,025 shares of unvested restricted stock that were granted on March 18, 2026 and vest in four equal installments beginning on the first anniversary of the grant.
• F4: Includes 3,063 remaining shares of unvested restricted stock that were granted on March 12, 2025 and were scheduled to vest in four equal annual installments beginning on the first anniversary of the grant.
• F5: Includes 1,717 remaining shares of unvested restricted stock that were granted on April 23, 2024 and were scheduled to vest in four equal annual installments beginning on the first anniversary of the grant.
• F6: These shares were acquired pursuant to an Employee Stock Ownership Plan Allocation.
• F7: Shares previously reported as indirectly beneficially owned through the reporting person's son are no longer reported because the reporting person has no pecuniary interest in such shares and therefore is not deemed the beneficial owner of those shares.
• F8: Options are fully vested.